Effect of Nigella sativa (Black Seed) on Subjective Feeling in Patients with Allergic Diseases

Phytotherapy Research

Volumn 17, Issue 10, 2003, Pages 1209-1214

  Kalus, Ulrich ^a,e   Pruss, Axel ^a   Bystron, Jaromir ^b   Jurecka, Moric ^c   Smekalova, Alice ^c   Lichius, Johannes Josef ^d   Kiesewetter, Holger ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c Municipal Outpatient Clinic   (Czech Republic)

^d Institute of Pharmacobiology   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Black seed; Inhalation allergy; Nigella sativa; Score of subjective feeling

Indexed keywords

CHOLESTEROL; CORTICOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; IMMERFIT; IMMUNOGLOBULIN E; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIGELLA SATIVA EXTRACT; PLACEBO; TRIACYLGLYCEROL;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ALLERGIC RHINITIS; ALLERGY; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BLACK CUMIN; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; EOSINOPHIL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROCORTISONE BLOOD LEVEL; LABORATORY DIAGNOSIS; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEDICINAL PLANT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; ANTI-ALLERGIC AGENTS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HUMANS; HYDROCORTISONE; IMMUNOGLOBULIN E; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NIGELLA SATIVA; PHYTOTHERAPY; PLANT OILS; RESPIRATORY HYPERSENSITIVITY; SEEDS; TRIGLYCERIDES;

NIGELLA; NIGELLA SATIVA;

EID: 0346095660     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1356     Document Type: Article

References (22)

1. Al-Ghamdi M-S. 2001. The anti-inflammatory, analgesic and antipyretic activity of Nigella sativa. J Ethnopharmacol 76: 45-48.
2. Badary OA. 1999. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol 67: 135-142.
3. Badary OA, Abdel-Naim AB, Abdel-Wahab MH, Hamada FM. 2000. The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats. Toxicology 143: 219-226.
4. Bufe A. 2000. A simple advice for the prevention of pollen-induced allergic rhinitis. Int Arch Allergy Immunol 121: 85-86.
5. Centers for Disease Control and Prevention. 1996. Asthma mortality and hospitalization among children and young adults - United States 1980-1993. MMWR 45: 350-353.
6. Charakravary N. 1993. Inhibition of histamine release from mast cells by nigellone. Ann Allergy 70: 237-242.
7. Daba MH, Abdel-Rahman MS. 1998. Hepatoprotective activity of thymoquinone in isolated rat hepatocytes. Toxicol Lett 95: 23-29.
8. El-Dakhakhny M, Naglaa I, Abdel Halim M, Abdel Halim MA. 2000. Nigella sativa L. oil protects against induced hepatotoxicity and improves serum lipid profile in rats. Arzneimittelforschung 50: 832-836.
9. El-Daly ES. 1998. Protective effect of cysteine and vitamin E, Crocus sativus and Nigella sativa extracts on cisplatin-induced toxicity in rats. J Pharm Belg 53: 87-93; discussion 93-95.
10. Ghosheh OA, Houdi AA, Crooks PA. 1999. High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seed (Nigella sativa). J Pharm Biomed Anal 19: 757-762.
11. Gottlieb DJ, Beiser AS, O'Connor GT. 1995. Poverty, race, and medication use are correlates of asthma hospitalization rates: A small area analysis of Boston. Chest 108: 28-35.
12. Handa SS, Kapoor VK. 1988. Pharmacognosy. Vallabh Prakashen: New Delhi.
13. Haq A, Abdullatif M, Lobo PI, Khabar KS, Sheth KV, al-Sedairy ST. 1995. Nigella sativa: Effects on human lymphocytes and polymorphonuclear leukocyte phagocytic activity. Immunopharmacology 30: 147-155.
14. Houghton PJ, Zarka R, de las Heras B, Hoult JR. 1995. Fixed oil of Nigella sativa and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. Planta Med 61: 33-36.
15. Ibraheim ZZ, Aly AM, Naddaf AR. 2001. The effect of oral administration of Nigella sativa L. seeds and oil on some blood parameters. Bull Pharm Sci 24: 29-39.
16. Jager L, Kroegel C. 1998. Leukotriene receptor antagonists and bronchial asthma. Arzneimittelforschung 48: 205-211.
17. Landrigan PJ. 1998. Gesundheit von Kindern und Umwelt: Eine neue Agenda für Präventive Forschung. Environ Health Perspects 106: 787-794.
18. Nagi MN, Alam K, Badary OA, al-Shabanah OA, al-Sawaf HA, al-Bekairi AM. 1999. Thymoquinone protects against carbon tetrachloride hepatotoxicity in mice via an antioxidant mechanism. Biochem Mol Biol Int 47: 153-159.
19. Salomi NJ, Nair SC, Panikkar KR. 1991. Inhibitory effects of Nigella sativa and saffron (Crocus sativus) in chemical carcinogenesis in mice. Nutr Cancer 16: 67-72.
20. Tennekoon KH, Jeevathayaparan S, Kurukulassooriya AP, Karunanayake EH. 1991. Possible hepatotoxicity of Nigella sativa seeds and Dregea volubilis leaves. J Ethnopharmacol 31: 283-289.
21. Worthen DR, Ghosheh OA, Crooks PA. 1998. The anti-tumor activity of some crude and purified components of black-seed, Nigella sativa L. Anticancer Res 18: 1527-1532.
22. Zaoui A, Cherrah Y, Mahassini N, Alaoui K, Amarouch H, Hassar M. 2002. Acute and chronic toxicity of Nigella sativa fixed oil. Phytomedicine 9: 69-74.